SEC Tracker
Get the app

Savara SVRA

Savara FY 2024: net loss $95.9M; diluted EPS −$0.48

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Savara reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$95.9MAgainst −$54.7M in FY 202310-K income statement, on EDGAR
  2. Diluted EPS−$0.48Against −$0.33 in FY 202310-K income statement, on EDGAR
  3. Cash and cash equivalents$15.1M−43% from $26.6M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$89.1MAgainst −$51.1M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Savara files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Opko Health OPK public float $540M, Dec 31, 2025
  2. Iovance Biotherapeutics IOVA public float $535M, Jun 30, 2025
  3. Elite Pharmaceuticals ELTP public float $534M, Sep 30, 2025
  4. Xencor XNCR public float $556M, Jun 30, 2025
  5. Evolus EOLS public float $560M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.